Psychotherapeutic Benefits of Opioid Agonist Therapy
暂无分享,去创建一个
[1] C. Treece,et al. DSM-III Personality Type and Dose Levels in Methadone Maintenance Patients , 1980, The Journal of nervous and mental disease.
[2] Andrzej Pilc,et al. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent , 2007, Neuropharmacology.
[3] M. Picker,et al. Behavioral assessment of temporal summation in the rat: sensitivity to sex, opioids and modulation by NMDA receptor antagonists , 2005, Psychopharmacology.
[4] S. Maxwell,et al. Optimizing Long-Term Response to Methadone Maintenance Treatment , 2002, Journal of addictive diseases.
[5] S. Schreiber,et al. Depression in methadone maintenance treatment patients: rate and risk factors. , 2007, Journal of affective disorders.
[6] Michael Lynskey,et al. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). , 2005, Drug and alcohol review.
[7] K. Goa,et al. Escitalopram , 2003, CNS drugs.
[8] L. Stein,et al. Enkephalin may mediate euphoria and drive-reduction reward , 1977, Nature.
[9] Peter Herscovitch,et al. Reduced Serotonin Type 1A Receptor Binding in Panic Disorder , 2004, The Journal of Neuroscience.
[10] C. Vanderwende,et al. Effect of narcotics on monoamine oxidase activity of mouse brain. , 1979, Research communications in chemical pathology and pharmacology.
[11] N. Mirza,et al. Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels? , 2005, Psychopharmacology.
[12] C. Yost,et al. Functional Inhibition by Methadone of N-Methyl-d-Aspartate Receptors Expressed in Xenopus Oocytes: Stereospecific and Subunit Effects , 2004, Anesthesia and analgesia.
[13] R. Resnick,et al. Buprenorphine: Pilot trials in borderline patients and opiate dependence: Treatment of a common disorder?: (474052004-001) , 1988 .
[14] P. Selwyn,et al. Medical care for injection-drug users with human immunodeficiency virus infection. , 1994, The New England journal of medicine.
[15] John Cornell,et al. A Systematic Review of Newer Pharmacotherapies for Depression in Adults: Evidence Report Summary: Clinical Guideline, Part 2 , 2000, Annals of Internal Medicine.
[16] I. Maremmani,et al. Methadone Dose and Retention During Treatment of Heroin Addicts with Axis I Psychiatric Comorbidity , 2000, Journal of addictive diseases.
[17] D. Kupfer,et al. Pet imaging of serotonin 1A receptor binding in depression , 1999, Biological Psychiatry.
[18] S. Schreiber,et al. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. , 2006, Drug and alcohol dependence.
[19] G. Gessa,et al. Psychiatric severity and treatment response in a comprehensive methadone maintenance treatment program. , 1997, Drug and alcohol dependence.
[20] F. Goodwin,et al. Supression of plasma cortisol in depressed patients by acute intravenous methadone infusion. , 1980, The American journal of psychiatry.
[21] E. Nunes,et al. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. , 2000, The American journal on addictions.
[22] S. Ikemoto,et al. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking , 1999, Brain Research Reviews.
[23] K. Humphreys,et al. Predictors of retention in methadone programs: a signal detection analysis. , 2006, Drug and alcohol dependence.
[24] M. Farré,et al. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. , 2002, Drug and alcohol dependence.
[25] H. Westenberg,et al. Glutamate and anxiety , 2004, European Neuropsychopharmacology.
[26] Pedro Rosa-Neto,et al. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. , 2004, Archives of general psychiatry.
[27] J. Bell,et al. A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. , 2002, Journal of affective disorders.
[28] J. Sweeney,et al. Psychiatric comorbidity in methadone maintained patients. , 1998, Journal of addictive diseases.
[29] E. Varga,et al. THE EFFECT OF CODEINE ON INVOLUTIONAL AND SENILE DEPRESSION , 1982, Annals of the New York Academy of Sciences.
[30] G. Bertschy,et al. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. , 1997, Journal of clinical psychopharmacology.
[31] F. Gasparini,et al. Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist , 2001, British journal of pharmacology.
[32] Anat Biegon,et al. Regionally selective increases in μ opioid receptor density in the brains of suicide victims , 1990, Brain Research.
[33] J. Rı́o,et al. Glutamate and Depression , 2005 .
[34] John H Krystal,et al. Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.
[35] F. Ciofalo. Methadone inhibition of 3H-5-hydroxytryptamine uptake by synaptosomes. , 1974, The Journal of pharmacology and experimental therapeutics.
[36] Sylvain Houle,et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. , 2006, Archives of general psychiatry.
[37] J. McKay,et al. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. , 2001, Drug and alcohol dependence.
[38] E. Callaway. Buprenorphine for depression: The un-adoptable orphan , 1996, Biological Psychiatry.
[39] Z. Pan,et al. μ-opioid-mediated inhibition of glutamate synaptic transmission in rat central amygdala neurons , 2005, Neuroscience.
[40] G. Nowak,et al. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling , 2004, Neuropharmacology.
[41] A. Gorman,et al. The d- and l- isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cord , 1997, Neuroscience Letters.
[42] Sean C. Sweetman,et al. Martindale: The Complete Drug Reference , 1999 .
[43] I. Maremmani,et al. Methadone doses and psychopathological symptoms during methadone maintenance. , 1993, Journal of psychoactive drugs.
[44] M. Gelkopf,et al. Benzodiazepine abuse in a methadone maintenance treatment clinic in Israel: characteristics and a pharmacotherapeutic approach. , 2002, The Israel journal of psychiatry and related sciences.
[45] J. Endicott,et al. Possible involvement of endorphin withdrawal or imbalance in specific premenstrual syndromes and postpartum depression. , 1981, Medical hypotheses.
[46] D. Segal,et al. The effect of methadone on the behavioral and neuroendocrine responses of manic patients , 1982, Psychiatry Research.
[47] F. Goodwin,et al. Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. , 1981, The American journal of psychiatry.
[48] P. Keck,et al. Open‐label pilot study of tramadol hydrochloride in treatment‐refractory obsessive‐compulsive disorder , 1997, Depression and anxiety.
[49] Y. Yun,et al. Inhibitory effects of ethaverine, a homologue of papaverine, on monoamine oxidase activity in mouse brain. , 2001, Biological & pharmaceutical bulletin.
[50] I. Maremmani,et al. Effectiveness of buprenorphine in double diagnosed patients . Buprenorphine as psychothropic drug , 2006 .
[51] M. Fache,et al. Glutamate, GABA, glycine and taurine modulate serotonin synthesis and release in rostral and caudal rhombencephalic raphe cells in primary cultures , 1993, Neurochemistry International.
[52] Y. Khazaal,et al. Worsening of obsessive–compulsive symptoms under methadone tapering , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[53] P. Whitton,et al. Chronic treatment with antidepressant drugs reversibly alters NMDA mediated regulation of extracellular 5-HT in rat frontal cortex , 2006, Brain Research Bulletin.
[54] P. Keck,et al. Rapid remission of OCD with tramadol hydrochloride. , 1999, The American journal of psychiatry.
[55] D. Metzger,et al. The Fifth Edition of the Addiction Severity Index. , 1992, Journal of substance abuse treatment.
[56] C. Eap,et al. Paroxetine Increases Steady-State Concentrations of (R)-Methadone in CYP2D6 Extensive but Not Poor Metabolizers , 2002, Journal of clinical psychopharmacology.
[57] H. Roffwarg,et al. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. , 1973, Archives of general psychiatry.
[58] J. Rabe-Jabłońska,et al. [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.
[59] Einführung in die psychiatrische Klinik : zweiunddreißig Vorlesungen , 1905 .
[60] P. Gillman,et al. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. , 2005, British journal of anaesthesia.
[61] T. Kosten,et al. Depressive symptoms during buprenorphine treatment of opioid abusers. , 1990, Journal of substance abuse treatment.
[62] Paul J Carlson,et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.
[63] A. Somogyi,et al. The Relationship Between Mood State and Plasma Methadone Concentration in Maintenance Patients , 2001, Journal of clinical psychopharmacology.
[64] S. Lukas,et al. Buprenorphine treatment of refractory depression. , 1995, Journal of clinical psychopharmacology.
[65] H. Emrich,et al. POSSIBLE ANTIDEPRESSIVE EFFECTS OF OPIOIDS: ACTION OF BUPRENORPHINE , 1982, Annals of the New York Academy of Sciences.
[66] P. Devoto,et al. Possible antidepressant activity of methadone. , 1982, European journal of pharmacology.
[67] J. Bell,et al. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence , 2004, European Psychiatry.
[68] E. Nunes,et al. Antidepressant treatment in methadone maintenance patients. , 1995, Journal of addictive diseases.
[69] M. Torrens,et al. Retention in a low-threshold methadone maintenance program. , 1996, Drug and alcohol dependence.
[70] M. Keshavan,et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.
[71] P. Krogsgaard‐Larsen,et al. Ketobemidone, methadone and pethidine are non-competitive N-methyl-d-aspartate (NMDA) antagonists in the rat cortex and spinal cord , 1995, Neuroscience Letters.